The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate health and economic outcomes of these 3 oral treatments in patients with mild to moderate COVID-19. Complete details of ICER’s systematic
literature search and protocol as well as the methodology and model structure for the economic evaluation are available on ICER’s website at https://icer.org/assessment/covid-19-2022/. ICER considered this review to be a Special Assessment because the epidemiological landscape and evidence base for potential treatments for COVID-19 are both rapidly evolving and will continue to change beyond the publication of the final report. In this article, we present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on April 12, 2022.
